
Wei Ying Jen, BM BCh, FRCPath
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
2019 | Royal College of Pathologists, GB, Fellowship of the Royal College of Pathologists |
2015 | National University of Singapore, Singapore, SG, Internal Medicine, Master of Medicine |
2015 | University of Oxford, Oxford, Oxfordshire, GB, Master of Arts |
2015 | Royal College of Physicians, GB, Membership of the Royal College of Physicians |
2012 | University of Oxford, Oxford, Oxfordshire, GB, Bachelor of Medicine and Bachelor of Surgery |
2009 | University of Oxford, Oxford, Oxfordshire, GB, Medical Sciences, Bachelor of Arts |
Postgraduate Training
2023-2024 | Fellow, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
2016-2019 | Senior Resident, Haematology, National University Cancer Institute, Singapore, Singapore, Singapore |
2013-2016 | Resident, Internal Medicine, National University Hospital, Singapore, Singapore |
2013-2013 | House Officer, General Medicine, National University Hospital, Singapore, Singapore |
2013-2013 | House Officer, KK Women's & Children's Hospital, Singapore, Singapore |
2012-2013 | House Officer, Singapore General Hospital, Singapore, Singapore |
Experience & Service
Academic Appointments
Adjunct Assistant Professor, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2023 - 2024
Senior Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2019 - 2023
Clinical Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2017 - 2019
Administrative Appointments/Responsibilities
Undergraduate Division Director, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2022 - 2024
System Block Lead, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2021 - 2023
Institutional Committee Activities
Key Opinion Leader, Singapore Translational Cancer Consortium, 2022 - Present
Member, Asia-Pacific Leukaemia Consortium, 2022 - Present
Member, Telemedicine Committee, 2020 - 2024
Member, NUHS App Workgroup, 2020 - 2024
Member, NCIS Right Siting Workgroup, 2019 - 2024
Member, Resident's Research Committee, 2018 - 2019
Member, NCIS Annual Research Meeting Scientific Committee, 2018 - 2020
Chairperson, Institutional Review Board, 2017 - 2019
Member, Residents' Welfare Committee, 2015 - 2016
Honors & Awards
2024 | EHA Educational Travel Grant, European Hematology Association |
2024 | Conquer Cancer – Eisai Inc. Endowed Merit Award, American Society of Clinical Oncology |
2023 | NCIS SHINE Incredible Care Award, Nominated by peers, allied health and supervisors to recognise staff who have contributed significantly to the institution and positively influenced their teams |
2022 | The Public Administration Medal (Bronze) (COVID-19), Prime Minister's Office, Singapore |
2022 | NCIS SHINE Incredible People Award, National University Cancer Institute, Singapore |
2020 | Quality Improvement Project Merit Award, National University Hospital |
2020 | Best Trainee Award, Chapter of Haematologists, College of Physicians, Academy of Medicine, Singapore |
2017 | Best Senior Resident Tutor Award, University Medicine Cluster, National University Hospital |
2016 | Junior Doctor Teaching Award, National University of Singapore Yong Loo Lin School of Medicine |
2014 | Best Poster Award, World Congress of Internal Medicine |
2012 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
2011 | Wellcome Trust Student Elective Prize, Wellcome Trust |
2010 | Glaxo Scholarship, St Catherine's College, University of Oxford |
2010 | Light Senior Scholarship, St Catherine's College, University of Oxford |
2009 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
2009 | Gibbs Prize, Pre-Clinical Faculty Office, University of Oxford |
2008 | College Exhibition, St Catherine's College, University of Oxford |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
- Brunmeir, R, Ying, L, Yan, J, Hee, YT, Lin, B, Kaur, H, Leong, QZ, Teo, WW, Choong, G, Jen, WY, Koh, LP, Tan, LK, Chan, E, Ooi, M, Yang, HH, Chng, WJ. EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML. Leukemia 39(3):650-662, 2025. e-Pub 2025. PMID: 39774797.
- Jen, WY, Sasaki, K, Ravandi-Kashani, F, Kadia, TM, Wang, S, Wang, W, Loghavi, S, Daver, N, DiNardo, C, Issa, GC, Abbas, HA, Nasnas, C, Bataller Torralba, A, Urrutia, S, Karrar, OS, Pierce, S, Kantarjian, HM, Short, NJ. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Advances 9(4):783-792, 2025. e-Pub 2025. PMID: 39631072.
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- Sahib, NM, Mohamed, JS, Rashid, MA, Jayalakshmi, Lin, YC, Chee, YL, Fan, BE, De Mel, S, Ooi, M, Jen, WY, Chow, EH. A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML. Cancer medicine 13(22), 2024. e-Pub 2024. PMID: 39560206.
- Alagha, R, Chan, WL, Edwin, TS, Lee, J, Jen, WY, Lip, CK, Smitasin, N, Somani, J. The Mote in Thy Brother's Eyes - Fusarium Solani in Leukemia Host. Infectious Diseases in Clinical Practice 31(2), 2023. e-Pub 2023.
Letters to the Editor
- Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, N, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.
Patient Reviews
CV information above last modified May 29, 2025